Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Clomiphene (Clomid) | Testosterone Enanthate | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 25-50 mg daily or every other day for PCT/HPTA restart protocols. Clinical hypogonadism treatment: 25-50 mg daily. | Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement. |
| Timing | Take at the same time daily. Evening dosing may reduce perception of visual side effects. No food timing requirements. | Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate. |
| Cycle Duration | PCT protocols: 4-8 weeks. Long-term SERM monotherapy: 3-12 months with periodic reassessment. Zuclomiphene accumulation is a concern beyond 6 months. | Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation. |
| Evidence Level | moderate_human | strong_human |
Clomiphene citrate is a racemic mixture of enclomiphene (trans-isomer, estrogen antagonist) and zuclomiphene (cis-isomer, weak estrogen agonist) that acts as a selective estrogen receptor modulator (SERM). It competitively occupies hypothalamic estrogen receptors, blocking the negative feedback of estradiol on GnRH pulse frequency. This disinhibition increases pulsatile GnRH release, stimulating anterior pituitary gonadotrope secretion of both LH and FSH, which in turn drives testicular testosterone synthesis and spermatogenesis. The zuclomiphene isomer has a much longer half-life (~30 days vs. ~10 days for enclomiphene), leading to tissue accumulation with chronic use.
Research indicates 25-50 mg daily or every other day for PCT/HPTA restart protocols. Clinical hypogonadism treatment: 25-50 mg daily.
Take at the same time daily. Evening dosing may reduce perception of visual side effects. No food timing requirements.
PCT protocols: 4-8 weeks. Long-term SERM monotherapy: 3-12 months with periodic reassessment. Zuclomiphene accumulation is a concern beyond 6 months.
Testosterone enanthate is a long-acting esterified testosterone prodrug with a heptanoic acid ester at the 17-beta hydroxyl group, extending its half-life to approximately 4.5-5 days. Upon hydrolysis by tissue esterases, free testosterone activates nuclear androgen receptors, upregulating anabolic gene transcription including myostatin suppression and IGF-1 induction. It also modulates the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback on GnRH and LH secretion.
Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement.
Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate.
Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →